Watch PTIX. Know when insiders buy.
One email the day a filing lands. Free.
Work order
54
WATCH · insiders 56, shorts 52
Insiders, 90 days
+$23K
net buying · 2 buys, 0 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $1.9MP/E 0.5DIV YIELD —FCF YIELD —REV TTM —NET INCOME $5.5MNET CASH —52W 0.13 – 4.37SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q1 2027 · Jun 30 | — | — | — | −$961K | −$964K | — | -0.53 | −$944K | — | — | Aug 19 |
| Q4 2026 · Mar 31derived | $0 | — | — | −$120K | $5.1M | — | 2.09 | $266K | — | — | Aug 14 |
| Q3 2026 · Dec 31 | $0 | — | — | −$925K | $2.2M | — | 1.14 | −$510K | — | — | Mar 9 |
| Q2 2026 · Sep 30 | $0 | — | — | −$1.1M | −$869K | — | -0.47 | −$812K | — | — | Mar 9 |
| Q1 2026 · Jun 30 | $0 | — | — | −$1.2M | −$5.1M | — | -1.37 | −$1.8M | — | — | Aug 19 |
| Q4 2025 · Mar 31 | $0 | — | — | −$1.4M | −$1.4M | — | -2.75 | −$1.1M | — | — | Aug 14 |
| Q3 2025 · Dec 31 | $0 | — | — | −$401K | −$850K | — | -0.16 | −$820K | — | — | Mar 9 |
| Q2 2025 · Sep 30 | $0 | — | — | −$355K | −$582K | — | -0.11 | −$186K | — | — | Mar 9 |
| Q1 2025 · Jun 30 | $0 | — | — | −$322K | −$324K | — | -0.06 | −$246K | — | — | Mar 9 |
| Q4 2024 · Mar 31 | $0 | — | — | −$1.7M | −$1.7M | — | -5.44 | −$1.7M | — | — | May 13 |
| Q3 2024 · Dec 31derived | $0 | — | — | −$1.2M | −$1.7M | — | -0.38 | −$1.1M | $94K | −$1.2M | Mar 31 |
| Q2 2024 · Sep 30 | $0 | — | — | −$1.4M | −$1.4M | — | -0.32 | −$656K | — | — | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2026 · to Mar 31 | $0 | — | −$4.5M | $1.4M | — | 0.59 | −$2.8M | $3K | −$2.8M | — | — |
| FY2025 · to Mar 31 | $0 | — | −$2.6M | −$3.6M | — | -0.67 | −$1.8M | — | — | — | — |
| FY2025 · to Dec 31 | $0 | — | −$5.7M | −$5.5M | — | -1.13 | −$4.2M | — | — | — | — |
| FY2024 · to Dec 31 | $0 | — | −$4.5M | −$5M | — | -1.15 | −$3.7M | $150K | −$3.9M | — | — |
| FY2023 · to Dec 31 | $0 | — | −$3.6M | −$3.6M | — | -0.82 | −$2M | $2K | −$2M | — | — |
| FY2022 · to Dec 31 | $0 | — | −$4.1M | −$4.5M | — | -0.31 | −$2.8M | — | — | — | — |
Every number comes from Protagenic Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.